TORONTO, Jan. 31, 2018 -- Beleave Inc. ("Beleave" or the "Company") (CSE:BE)(OTCQX:BLEVF) is pleased to announce that it has received notification from Health Canada that the Company's pre-sale inspection has been scheduled for February 8, 2018. The issuance of a sales license under the Access to Cannabis for Medical Purposes Regulations is in part dependent upon the completion of a satisfactory pre-sale inspection by Health Canada.
About Beleave
Beleave Inc. is a biotech company and Beleave's wholly-owned subsidiary Beleave Kannabis Corp. (formerly First Access Medical Inc.) is a licensed producer pursuant to the ACMPR. Beleave's purpose-built facility is located in Hamilton, Ontario.
For further information please contact:
Sebastian de Kloet
Phone: (905) 979 - 5173
Email: [email protected]
beleave.com
Forward-Looking Statements
This news release contains "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). The use of any of the words "plan", "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and other similar words, or statements that certain events or conditions "may" or "will" occur are intended to identify forward-looking information. These statements are only predictions. Although the Company believes that the expectations and assumptions on which the forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. These risks and uncertainties include, but are not limited to, the Company's ability to satisfy the conditions associated with its cultivation license, the Company's ability to obtain a sales license and the related timing considerations, the availability of further financing, consumer interest in its products, competition, regulation, operational and technological risks, and anticipated and unanticipated costs and delays. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. This information speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents, which can be found under the Company's profile on www.sedar.com.


SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Washington Post Publisher Will Lewis Steps Down After Layoffs
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Anta Sports Expands Global Footprint With Strategic Puma Stake
Samsung Electronics Shares Jump on HBM4 Mass Production Report 



